Nevasoft, a Turkish startup semi-finalist from the second cohort of Ventures Thrive, has received a $100,000 investment at a $1.5 million valuation during the pre-seed stage.

This means that Nevasoft has successfully achieved one of its KPI goals (‘Completing the $100,000 Investment Pre-Seed Stage’), as established during its Ventures Thrive experience, and set a key milestone in what is set to be a long and fruitful journey of growth.

Nevasoft is the brains behind the cutting-edge ‘Blood Analysis Software’ - a decision support system designed to assist Hematology and Oncology specialists in diagnosing blood cancers (e.g. Leukemia and Lymphoma) as well as other blood disorders.

The ‘Blood Analysis Software’ integrates three types of medical reports used during the diagnostic process - blood tests, blood microscope images, and flow cytometry results - into a single platform. The software then analyses said reports using AI.

This analysis provides users the advantage of early diagnosis by determining the patient’s current disease status and predicting future trends. Additionally, it enables specialists to make faster and more accurate diagnoses.